Cover

Food Insecurity and the Dangers of Infant Formula Dilution

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to the manufacturer Gilead Sciences.

January 30th 2023

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Demystifying Infant Formula

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

October 11th 2022

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions

FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older

The federal agency has assigned a target action date of January 31, 2026, for a decision.

FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to the manufacturer Gilead Sciences.

January 30th 2023

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Demystifying Infant Formula

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

October 11th 2022

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions

FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older

The federal agency has assigned a target action date of January 31, 2026, for a decision.